Publications by authors named "Jiao-Tian Xu"
Previous studies have shown that neural stem cell transplantation has the potential to treat Parkinson's disease, but its specific mechanism of action is still unclear. Stromal cell-derived factor-1 and its receptor, chemokine receptor 4 (CXCR4), are important regulators of cell migration. We speculated that the CXCR4/stromal cell-derived factor 1 axis may be involved in the therapeutic effect of neural stem cell transplantation in the treatment of Parkinson's disease.
View Article and Find Full Text PDFArticle Synopsis
- Neural stem cell (NSC) transplantation shows promise for treating Parkinson's disease, but many NSCs differentiate into glial cells and die due to inflammation post-transplant.
- In this study, researchers transplanted NSCs and microglial cells that overexpress the Nurr1 gene into the brains of rats with Parkinson's, evaluating the effects through various scientific methods.
- Results indicated that this combined therapy improved behavior in PD rats, increased dopamine-producing cells, and reduced inflammatory cells, suggesting a new strategy for cell replacement therapy in Parkinson's disease.
Introduction: Neural stem cells (NSCs) are the most promising cells for cell replacement therapy for Parkinson's disease (PD). However, a majority of the transplanted NSCs differentiated into glial cells, thereby limiting the clinical application. Previous studies indicated that chronic neuroinflammation plays a vital role in the degeneration of midbrain DA (mDA) neurons, which suggested the developing potential of therapies for PD by targeting the inflammatory processes.
View Article and Find Full Text PDF